BACKGROUND

Pharmaceutical providers often receive patient complaints regarding undesirable side effects or medication-related side effects for which advanced therapies may be considered. A multi-center research team identified key indicators of inadequate symptom management (MS) and non-motor symptoms (NMS) requiring advanced PD therapy. The symptoms were identified during the study development phase, and a draft clinician-reported tool was developed (Onuk et al., 2014).

METHODS: PHASE 1

• Delphi Study

**Delphi Study**

- Development of a Clinician-reported Screening Tool to Identify Patients with Parkinson's Disease Inadequately Controlled on Oral Medications
- Presenting at the Movement Disorders Society Congress • June 5, 2017 • Vancouver, BC, Canada

**Cognitive Interviews**

- Development of a Clinician-reported Screening Tool to Identify Patients with Parkinson's Disease Inadequately Controlled on Oral Medications
- Presenting at the Movement Disorders Society Congress • June 5, 2017 • Vancouver, BC, Canada

**Implementation in clinical practice**

- Developing evidence-based, iterative, clinician-reported tool development methods (Powers et al. 2017)
- Identifying an international panel of MDS with extensive experience of advanced PD therapy
- Developing and implementing a clinician-reported tool development method

**RESULTS**

- Development of a clinician-reported screening tool for identifying patients inadequately controlled on oral medications and eligible for advanced PD therapy (Onuk et al., 2014).
- The tool was based on the Delphi study, which involved experts in 10 EU countries and Portugal on oral medications to identify patients likely to benefit from advanced therapies in June 2017.

**STRENGTHS**

- Use of evidence-based, interactive, clinician-reported tool development methods (Powers et al. 2017)
- Identification of an international panel of MDS with extensive experience of advanced PD therapy
- Strategic commitment and prioritization of international clinical needs
- Development of an evidence-based tool as an important contributor to the development of evidence-based standards of care for advanced PD therapy

**LIMITATIONS**

- Determination of clinical relevance and influence on daily life (for the clinician)
- Further feedback on weighting of response options for indicators for inadequately controlled on oral PDs and eligibility for advanced PD therapy

**NEXT STEPS FOR TOOL DEVELOPMENT**

- Development of an evidence-based, interactive, clinician-reported tool development method as an international tool for identifying patients with Parkinson's disease inadequately controlled on oral medications and eligible for advanced PD therapy
- Development of a tool that identifies patients with Parkinson's disease inadequately controlled on oral medications and eligible for advanced PD therapy

**REFERENCES**


**DISCLOSURES**

The study was supported by AbbVie, Inc. Abbott participated in study design, research, data collection, analysis, and interpretation of data, writing, reviewing, and editing the manuscript. All authors had full access to all data and all authors were responsible for the decision to submit the manuscript for publication. Clinical trial information: NCT02300768.